Navigation Links
BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer

BURLINGAME, Calif., Nov. 7 /PRNewswire/ -- BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that Michael C. Venuti, Ph.D., has joined the Company as its Chief Executive Officer and member of the Board of Directors. Dr. Venuti succeeds Peter D. Staple, who will continue his involvement with the Company as an investor and Board member. Dr. Venuti previously served as Chief Executive Officer of Discovery Partners International, a small molecule-based drug discovery services company.

Fred Craves, Managing Director and Founder of Bay City Capital, which is a major investor in BioSeek, commented, "We welcome Michael to BioSeek, as we believe his leadership and specific experience in drug discovery will be important as BioSeek strives to expand its proprietary drug discovery activities. This new direction was highlighted by our recent research collaboration with Amylin Pharmaceuticals to discover novel peptide therapeutics. We thank Peter Staple for his important contributions to BioSeek, including taking the Company to a new level through validating corporate partnerships, including our relationship with Amylin."

"It's gratifying to have an individual with Michael's background and talent join us as the Company advances into an exciting new phase of development," added Peter Staple.

"I look forward to leading BioSeek in its new drug discovery-focused direction and anticipate these new initiatives will lead us to both additional partnerships and revenue-generating contracts in the future," commented Dr. Venuti. "The launching of our proprietary development programs utilizing our BioMAP(R) human biology screening systems will also provide us with additional internal value drivers."

Since the Discovery Partners merger with Infinity Pharmaceuticals in September 2006, Dr. Venuti has served as a consultant to TPG Growth Biotech Ventures, as well as to a number of biotech companies. Before becoming CEO of Discovery Partners, Dr. Venuti served as Chief Scientific Officer, and had been a member of its board of directors before becoming CSO. Prior to joining Discovery Partners, he served as General Manager of Celera Genomics Group's South San Francisco site after its acquisition of Axys Pharmaceuticals, Inc. He served as Senior Vice President, Research and Preclinical Development, of Axys Pharmaceuticals prior to its acquisition by Celera. In this capacity, he was responsible for all small molecule target identification, medicinal chemistry, drug discovery and preclinical development activities. Prior to joining Axys, Dr.Venuti was Director of Bioorganic Chemistry at Genentech, Inc., and had begun his research career in medicinal chemistry at Syntex.

Dr. Venuti holds an A.B. from Dartmouth College, a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, and completed postdoctoral training in the Institute of Organic Chemistry at Syntex Research. He is on the board of directors of Infinity Pharmaceuticals and serves as Executive Scientific Advisor to BIO Ventures for Global Health, a non-profit advocacy group focused on drug discovery and development for neglected diseases. Dr. Venuti holds an appointment as Adjunct Professor of Chemistry in the Department of Pharmaceutical Chemistry at the University of California, San Francisco.

About BioSeek

BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company's BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners' pipelines, and in the Company's internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases, and related indications.

For more information, go to

BioSeek Contacts:

BioSeek, Inc.

Michael C. Venuti, Ph.D.

Chief Executive Officer

Tel: 650-552-0754


MacDougall Biomedical Communications

Jennifer Greenleaf

Tel: 508.647.0209


SOURCE BioSeek, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 Story ... operating models within the health care industry is causing ... efficiency , Deloitte offers a suite of solutions ... issues impacting efficient cost optimization: labor resource analysis, revenue ... services facilitate better outcomes and better economics ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
Breaking Medicine Technology: